AZD5991

PreclinicalSmall molecule

AZD5991 is one of 21 small molecule programs targeting Refractory Acute Myeloid Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory Acute Myeloid LeukemiaRecruiting

Refractory Acute Myeloid LeukemiaPreclinical

Recruiting

Competition

Competitive Landscape

20 competitors in Refractory Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 1

2 2

Cytosar

Teva

Phase 1

2 3

Mitoxantrone Hydrochloride Liposome

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2

1 4

Revuforj

SSyndax Pharmaceuticals

Phase 1

2 5

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

2 6

Dacogen

Sun Pharmaceutical Industries, Inc.

Preclinical

1 7

Peony

Takeda

Preclinical

1 8

Xospata

Astellas

Preclinical

1 9

Cerubidine

HHikma Pharmaceuticals LLC

Preclinical

1 10

AG-120

Institut de Recherches Internationales Servier

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

PreclinicalRecruiting

Refractory Acute Myeloid Leukemia

NCT03013998

Clinical

Trials by Indication[1]

Relapsed or Refractory1 trial

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT03218683·70 enrolled

Refractory Acute Myeloid Leukemia1 trial

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Recruiting·BBeat AML, LLC·Preclinical·NCT03013998·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD5991. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD5991 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD5991. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

AZD5991

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Relapsed or Refractory1 trial

Refractory Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News